KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Asset Writedowns and Impairment (2022 - 2025)

Charles River Laboratories International (CRL) has 4 years of Asset Writedowns and Impairment data on record, last reported at $254.5 million in Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment rose 842.67% year-over-year to $254.5 million; the TTM value through Dec 2025 reached $259.1 million, up 635.54%, while the annual FY2025 figure was $259.1 million, 1653.62% up from the prior year.
  • Asset Writedowns and Impairment reached $254.5 million in Q4 2025 per CRL's latest filing, up from $2.4 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $254.5 million in Q4 2025 and bottomed at -$8.0 million in Q4 2023.
  • Average Asset Writedowns and Impairment over 4 years is $24.5 million, with a median of $3.2 million recorded in 2023.
  • Peak YoY movement for Asset Writedowns and Impairment: tumbled 233.55% in 2023, then soared 842.67% in 2025.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $6.0 million in 2022, then crashed by 233.55% to -$8.0 million in 2023, then skyrocketed by 438.47% to $27.0 million in 2024, then skyrocketed by 842.67% to $254.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $254.5 million in Q4 2025, $2.4 million in Q3 2025, and $184000.0 in Q2 2025.